您目前的位置: 首页 » 师资队伍 » 博士生导师 » 正文

易伟


易伟 教授

电子邮箱:yiwei@gzhmu.edu.cn

工作经历:

10/2022-至今     广州医科大学药学院副院长

10/2018-至今     呼吸疾病国家重点实验室PI

11/2016-至今     广州医科大学“南山学者”特聘教授

10/2014-10/2016  中国科学院上海药物研究所 副研究员          

09/2013-09/2014  中科院受体与结构功能重点实验室 特聘副研究员

09/2013-10/2014  中国科学院上海药物研究所 助理研究员                          

               07/2011-07/2013  中国科学院上海药物研究所 博士后


研究兴趣:

    围绕“靶向设计与合成—新药筛选与发现—作用靶点结构解析—分子机制探究”这一当代药物研发流程进行相互渗透、有机融合,同时结合计算机辅助药物设计、药物化学、有机合成化学、分子药理学、结构生物学等各个学科的交叉优势,而聚焦开展“基于核受体蛋白(GRPPARγ)的高效安全的靶向创新药物设计、合成与发现”研究工作。近五年来取得了阶段性研究成果及进展如下a)开发了一系列原子/步骤经济性的现代药物合成新方法及新技术,并将其成功应用于各类新型优势骨架与DNA编码化合物库(DELs)的高效构建及具有明显靶向GR或PPARγ蛋白特征的药学官能团的一步引入b)解析了多个潜力小分子配体[如皮质醇(Cortisol)、糠酸莫米松(MF)、VSP-51、VSP-77等]与靶标蛋白GR或PPARγ的高分辨率复合物晶体结构c)以构建的多样性化合物库为基础及解析的复合物晶体结构信息为指导,成功开发了数个高效低毒、机制清晰的新型化学分子或上市药物作为靶标GR或PPARγ的候选新药化合物(以PPARγ为靶点的新型配体作为抗II型糖尿病新药发现:VSP-51、VSP-51-2、VSP-77及抗菌药物-芬替康唑;以GR为靶点的新型配体作为抗炎新药发现:VSP-22、VSGC12VSG-158)。

上述研究取得的相关成果已发表SCI收录研究论文近120篇,总他引率5000余次,h指数为37(来自Google Scholar查询数据)。其中以第一或通讯作者(含共同)在Chem、Cell Res.、Cell Discov.、Angew. Chem. Int. Ed.、Chem. Sci.、PNAS、APSB等国际著名杂志发表研究论文90余篇,包括IF>10研究论文20 (自2016年底申请人全职加入广州医科大学组建团队独立开展工作以来已发表的研究论文请见其课题组网站(Yi Group):http://www.gzhmu-ygz-group.cn/publications);申请国内外发明专利20余项,其中以GR为靶标的抗炎新药开发专利已成功转让,总金额5000人民币(里程碑式支付,其中候选分子现已进入临床III期);已主持国家自然科学面上及青年基金等项目,也先后获得了赛诺菲·安万特-中科院上海生命科学研究院优秀青年科学家(2015年)、中国科学院青年创新促进会基金(2016年)、广东省自然科学杰出青年基金(2017年)、广东省“基于靶蛋白结构的创新药物设计与发现”创新团队(2019年)、 “岭南英杰工程”国家级后备人才(2019年)等多个针对优秀青年科研人才的项目资助及称号此外,相关研究成果自2019年以来在国内外大型学术会议如世界华人药物化学会议、《药学学报》药学前沿论坛暨表观遗传与生物医药研发国际学术大会、全国药物化学会议、全国化学生物学会议均做了专题报告。


学术兼职:

2023.03-至今 广州医科大学学术委员会委员

2019.03-至今《Acta Pharmaceutica Sinica B》青年编委 (IF = 14.903)

2021.01-至今《Chinese Chemical Letters》青年编委 (IF = 8.455)


代表性科研项目:

[1] 国家自然科学基金面上项目,82273795,新型靶向GR配体结合域(LBD)-螺旋-1的选择性调控剂的 设计与发现及其作用机制研究, 2023-012026-1252万元,主持

[2] 广州市"岭南英杰"工程国家级后备人才项目, Q847003,基于结构的创新药物设计与发现,2019-052023-05125万元,主持

[3] 广东省高等教育“创新强校工程”创新团队项目,B195001282,基于靶蛋白结构的新药设计与发现创新团队,2019-012021-1250万元,主持

[4] 国家自然科学基金面上项目,21877020,基于结构的新型PPARγ选择性调控剂靶向吲哚衍生物的设计、合成及其抗II型糖尿病作用机制探究, 2019-012021-1265万元,主持

[5] 广东省自然科学杰出青年基金,2017A030306031,基于结构的新型PPARγ选择性调控剂作为抗II型糖尿病候选药物发现及其调控机制研究,2017-052021-05100万,主持

[6] 中国科学院青年创新促进会会员基金,2016261,基于核受体结构的创新药物设计与发现,2016-012019-1280万元,主持

[7] 国家自然科学基金青年项目,81502909,基于结构的新型选择性GR调控剂氢化可的松衍生物的设计、合成及其抗炎机制研究,2016-012018-1218.5万元,主持

[8] 中科院药物创新研究院自部署项目,CASIMM0120152031VSP-51-2作为抗糖尿病先导化合物开发,2015-082016-08100万元,主持

[9] 上海市自然基金面上项目,15ZR1447800,新型PPARγ调控剂C2位功能化的VSP-51吲哚衍生物的设计、合成及构效关系研究,2015-012017-1210万元,主持


代表性论著:

[1] Zhi Zhou, Yuang Gu, Liexin Wu, Yan Wang, Huiying Xu, Lei Ma, Zhaoyong Zhang, Jincun Zhao, Wei Zhang, Wei Peng, Guang Yang, Xiyong Yu, Hongtao Xu*, Wei Yi*; Organo-Se BTSAs-enabled performance: from Racemic and asymmetric synthesis to click-based application. Chem, 2023, DOI: 10.1016/j.chempr.2023.07.022.

[2] Peixiang Ma, Shuning Zhang, Qianping Huang, Yuang Gu, Zhi Zhou, Wei Hou*, Wei Yi*, Hongtao Xu*. Evolution of chemistry and selection technology for DNA-encoded library. Acta Pharm. Sin. B, 2023, DOI: 10.1016/j.apsb.2023.10.001.

[3] Chun-Lei Song, Qiao-Tong He, Zhongyi Zeng, Jing-Yan Chen, Tian Wen, Yu-Xiao Huang, Liu-Chun Zhuang, Wei Yi*, Yue-Peng Cai*, Xu-Jia Hong*; Isolated Diatomic Zn-Co Metal–Nitrogen/Oxygen Sites with Synergistic Effect on Fast Catalytic Kinetics of Sulfur Species in Li-S Battery. J. Energy Chem., 2023, 79, 501-505.

[4] Zhongyi Zeng, Hui Gao, Zhi Zhou*, Wei Yi*; Intermolecular Redox-Neutral Carboamination of C−C Multiple Bonds Initiated by Transition-Metal-Catalyzed C−H Activation. ACS Catal., 2022, 12, 14754−14772.

[5] Haifang Meng#, Huiying Xu#, Zhi Zhou#, Zhenhao Tang, Yidi Li, Yu Zhou*, Wei Yi* and Xiaowei Wu*. Recyclable rhodium-catalyzed C-H activation/[4+2] annulation with unconventional regioselectivity at ambient temperature: experimental development and mechanistic insight. Green Chem., 2022, 24, 7012-7021.

[6] Hui Gao#; Shuang Lin#; Shuning Zhang#; Weijie Chen; Xiawen Liu; Guang Yang; Richard A. Lerner; Hongtao Xu*; Zhi Zhou*; Wei Yi*; Gem-Difluoromethylene Alkyne-Enabled Diverse C-H Functionalization and Application to the on-DNA Synthesis of Difluorinated Isocoumarins. Angew. Chem. Int. Ed., 2021, 60, 1959-1966.

[7] Lei Ma, Yuling Lian, Junyuan Tang, Fangyuan Chen, Hui Gao, Zhi Zhou*, Ning Hou* and Wei Yi*. Identification of the Anti-Fungal Drug Fenticonazole Nitrate as a Novel PPARγ-Modulating Ligand With Good Therapeutic Index: Structure-Based Screening and Biological Validation. Pharmacol. Res., 2021, 173, 105860.

[8] Liexin Wu#; Huiying Xu#; Hui Gao; Liping Li; Weijie Chen; Zhi Zhou*; Wei Yi*; Chiral Allylic Amine Synthesis Enabled by the Enantioselective Cp*Rh(III)-Catalyzed Carboaminations of 1,3-Dienes. ACS Catal., 2021, 11, 2279-2287.

[9] Fei Zhao#*; Zhi Zhou#; Yangbin Lu#; Jin Qiao; Xiaoning Zhang; Xin Gong; Siyu Liu; Shuang Lin; Xiaowei Wu*; Wei Yi*; Chemo, Regio, and Stereoselective Assembly of Polysubstituted Furan-2(5H)ones Enabled by Rh(III)-Catalyzed Domino C−H Alkenylation/Directing Group Migration/Lactonization: A Combined Experimental and Computational Study. ACS Catal., 2021, 11, 13921−13934.

[10] Huiying Xu#; Weijie Chen#; Mengyao Bian#; Hongtao Xu; Hui Gao; Ting Wang; Zhi Zhou*; Wei Yi*; Gem-Difluorocyclopropenes as Versatile β-Monofluorinated Three sp2 Carbon Sources for Cp*Rh(III)-Catalyzed [4+3] Annulation: Experimental Development and Mechanistic Insight. ACS Catal., 2021, 11, 14694-14701.

[11] Haowen Jiang#; X. Edward Zhou#; Jingjing Shi#; Zhi Zhou#; Guanguan Zhao; Xinwen Zhang; Yili Sun; Kelly Suino-Powell; Lei Ma; Hui Gao; Xiyong Yu; Jia Li*; Jingya Li*; Karsten Melcher; H. Eric Xu*; Wei Yi#*; Identification and Structural Insight of an Effective PPARγ Modulator with Improved Therapeutic Index for Anti-Diabetic Drug Discovery. Chem. Sci., 2020, 11, 2260-2268.

[12] Yuanzheng He#*; Jingjing Shi#; Quang Tam Nguyen#; Erli You; Hongbo Liu; Xin Ren; Zhongshan Wu; Jianshuang Li; Wenli Qiu; Sok Kean Khoo; Tao Yang; Wei Yi*; Feng Sun; Zhijian Xi; Xiaozhu Huang; Karsten Melcher; Booki Min*; H. Eric Xu*; Development of Novel Highly Potent Glucocorticoids for Steroid-Resistant Severe Asthma. PNAS, 2019, 116, 6932-6937.

[13] Guangfan Zheng#; Zhi Zhou#; Guoxun Zhu#; Shuailei Zhai; Huiying Xu; Xujing Duan; Wei Yi*; Xingwei Li*; Rhodium(III)-Catalyzed Enantio- and Diastereoselective C–H Cyclopropylation of N-Phenoxylsulfonamides: Combined Experimental and Computational Studies. Angew. Chem. Int. Ed., 2020, 59, 2890-2896.

[14] Wei Yi*; Weijie Chen; Fu-Xiaomin Liu; Yuting Zhong; Dan Wu; Zhi Zhou*; Hui Gao*; Rh(III)-Catalyzed and Solvent-Controlled Chemoselective Synthesis of Chalcone and Benzofuran Frameworks via Synergistic Dual Directing Groups Enabled Regioselective C–H Functionalization: A Combined Experimental and Computational Study. ACS Catal., 2018, 8, 9508-9519.

[15] Xu Zhang; Zhiqiang Wang; Kun Xu; Yuquan Feng; Wei Zhao; Xuefeng Xu; Yanlei Yan; Wei Yi*; HOTf-catalyzed sustainable one-pot synthesis of benzene and pyridine derivatives under solvent-free conditions. Green Chem., 2016, 18, 2313-2316.

[16] Jie Zhou; Jingjing Shi; Zisong Qi; Xingwei Li*; H. Eric Xu; Wei Yi*; Mild and efficient Ir(III)-catalyzed direct C-H alkynylation of N-phenoxyacetamides with terminal alkyne. ACS Catal., 2015, 5, 6999-7003.

[17] Siwei Zhang, Jie Zhou †, Jingjing Shi, Min Wang, H. Eric Xu, Wei Yi *; Rh(III)-catalyzed direct C−H cyanation of N-methoxybenzamides using N-cyano-N-phenyl-p-toluenesulfonamide. Chinese J. Catal., 2015, 36, 1175-1182.

[18] Li-Hua Zhao#; X Edward Zhou#; Wei Yi#; Zhongshan Wu; Yue Liu; Yanyong Kang; Li Hou; Parker W de Waal; Suling Li; Yi Jiang; Adrian Scaffidi; Gavin R Flematti; Steven M Smith; Vinh Q Lam; Patrick R Griffin; Yonghong Wang; Jiayang Li; Karsten Melcher*; H. Eric Xu*; Destabilization of Strigolactone Receptor DWARF14 by Binding of Ligand and E3-Ligase Signaling Effector DWARF3. Cell Res., 2015, 25, 1219-1236.

[19] Yuanzheng He*; Jingjing Shi; Wei Yi*; Xin Ren; Xiang Gao; Jianshuang Li; Nanyan Wu; Kevin Weaver; Qian Xie; Sok Kean Khoo; Tao Yang; Xiaozhu Huang; Karsten Melcher; H. Eric Xu*; Discovery of a Highly Potent Glucocorticoid for Asthma Treatment. Cell Discov., 2015, 1, 15035.

[20] Yuanzheng He*; Wei Yi*; Kelly Suino-Powell; X. Edward Zhou; W. David Tolbert; Xiaobo Tang; Jing Yang; Huaiyu Yang; Jingjing Shi; Li Hou; Hualiang Jiang; Karsten Melcher; H. Eric Xu*; Structures and Mechanism for the Design of Highly Potent Glucocorticoids. Cell Res., 2014, 24, 713-726.